Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY PLATFORM FOR SUBLINGUAL KETAMINE
* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS SEELOS' KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC NEUROPATHIC PAIN
* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE SUBLINGUAL KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS
* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT, SEELOS WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION
Source text for Eikon: ID:nPn7sB5Xna Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;;))